Slide of the Month Archive

March 2011 Optimal times for between-agency dialogue

April 2011 Lowest number of NAS approvals in 2010 by both FDA and EMA in ten years

May 2011 Seven steps in the benefit-risk assessment of medicines

June 2011 Median times to submission and licensing for 70 new active substances approved in five markets from 1997 to 2010

July 2011 Impact of priority, accelerated, and fast-track review status on US FDA approval times

August 2011 Process mapping of registration to reimbursement for new pharmaceuticals in UKMarch 2011 Optimal times for between-agency dialogue

September 2011 The percentage of NASs approved by CDER by one-cycle review process has increased

October 2011 Comparison of median time for submission to EM countries from 1^st world-wide approval (2006-2007 vs 2008-2009)

November 2011 Regulatory review process: what are enablers?

December 2011 Key factors likely to impact medicines development